Company intelligence / Profile preview

Uniquity One

Pennsylvania, United Stateswmtips.com ↗

Ownership: Private
Development stage: Phase 2

Overview

FDA has accepted Phase 2 IND application for solrikitug, a monoclonal antibody targeting TSLP. Phase 2 clinical trials in COPD and asthma are planned to start soon.

Therapeutic areas: Pulmonology
Modalities: Monoclonal antibodies
Industry: Biotech

Drug pipeline

1 asset

solrikitug

Phase 2

Indications: Chronic obstructive pulmonary disease

Partnerships

Merck (MSD) - licensed solrikitug from them

Beyond the preview

Go deeper on Uniquity One.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Uniquity One.

Explore the full profile